• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

比较替代群体建模方法在实施 A 级 IVIVC 中的应用,以及使用去卷积和卷积方法评估时间标度因子。

Comparison of Alternative Population Modeling Approaches for Implementing a Level A IVIVC and for Assessing the Time-Scaling Factor Using Deconvolution and Convolution-Based Methods.

机构信息

R&D, Pharmacometrica, Lieu-dit Longcol, 12270, La Fouillade, France.

出版信息

AAPS J. 2020 Apr 15;22(3):67. doi: 10.1208/s12248-020-00445-0.

DOI:10.1208/s12248-020-00445-0
PMID:32297044
Abstract

Different approaches based on deconvolution and convolution analyses have been proposed to establish IVIVC. A new implementation of the convolution-based model was used to evaluate the time-scaled IVIVC using the convolution (method 1) and the deconvolution-based (method 2) approaches. With the deconvolution-based approach, time-scaling was detected and estimated using Levy's plots while with the convolution-based approach, time-scaling was directly determined by a time-scaling sub-model of the convolution integral model by nonlinear regression. The objectives of this study were (i) to show how time-scaled deconvolution and convolution-based approaches can be implemented using population modeling approach using standard nonlinear mixed-effect modeling software such as NONMEM and R, and (ii) to compare the performances of the two methods for assessing IVIVC using complex in vivo drug release process. The impact of different PK scenarios (linear and nonlinear PK disposition models, and increasing levels of inter-individual variability (IIV) on in vivo drug release process) was considered. The performances of the methods were assessed by computing the prediction error (%PE) on C, AUC, and partial AUC values. The mean %PE values estimated with the two methods were compliant with the IVIVC validation criteria. However, different from convolution-based, deconvolution-based approach showed that (i) the increase of IIV on in vivo drug release significantly affects the maximal %PE values of C leading to failure of IVIVC validation, and (ii) larger %PE values for C were associated to complex nonlinear PK disposition models. These results suggest that convolution-based approach could be considered at preferred approach for assessing time-scaled IVIVC.

摘要

已经提出了基于去卷积和卷积分析的不同方法来建立 IVIVC。使用基于卷积的新模型实现来评估使用卷积(方法 1)和基于去卷积的(方法 2)方法进行时间缩放的 IVIVC。在基于去卷积的方法中,通过 Levy 图检测和估计时间缩放,而在基于卷积的方法中,时间缩放通过卷积积分模型的时间缩放子模型通过非线性回归直接确定。本研究的目的是:(i)展示如何使用群体建模方法使用标准的非线性混合效应建模软件(如 NONMEM 和 R)来实现时间缩放的去卷积和基于卷积的方法;(ii)比较这两种方法在评估使用复杂体内药物释放过程的 IVIVC 时的性能。考虑了不同 PK 情景(线性和非线性 PK 处置模型,以及个体间变异性(IIV)水平的增加)对体内药物释放过程的影响。通过计算 C、AUC 和部分 AUC 值的预测误差(%PE)来评估方法的性能。这两种方法估计的平均%PE 值符合 IVIVC 验证标准。然而,与基于卷积的方法不同,基于去卷积的方法表明:(i)体内药物释放的 IIV 增加会显著影响 C 的最大%PE 值,导致 IVIVC 验证失败;(ii)C 的较大%PE 值与复杂的非线性 PK 处置模型相关。这些结果表明,基于卷积的方法可以被认为是评估时间缩放 IVIVC 的首选方法。

相似文献

1
Comparison of Alternative Population Modeling Approaches for Implementing a Level A IVIVC and for Assessing the Time-Scaling Factor Using Deconvolution and Convolution-Based Methods.比较替代群体建模方法在实施 A 级 IVIVC 中的应用,以及使用去卷积和卷积方法评估时间标度因子。
AAPS J. 2020 Apr 15;22(3):67. doi: 10.1208/s12248-020-00445-0.
2
Comparison of Deconvolution-Based and Absorption Modeling IVIVC for Extended Release Formulations of a BCS III Drug Development Candidate.基于去卷积和吸收建模的IVIVC在BCS III类药物开发候选物缓释制剂中的比较
AAPS J. 2015 Nov;17(6):1492-500. doi: 10.1208/s12248-015-9816-7. Epub 2015 Aug 20.
3
Convolution-based approaches for in vivo-in vitro correlation modeling.基于卷积的体内-体外相关性建模方法。
Adv Exp Med Biol. 1997;423:53-65. doi: 10.1007/978-1-4684-6036-0_5.
4
Deconvolution Analysis by Non-linear Regression Using a Convolution-Based Model: Comparison of Nonparametric and Parametric Approaches.基于卷积模型的非线性回归解卷积分析:非参数和参数方法的比较。
AAPS J. 2019 Dec 9;22(1):9. doi: 10.1208/s12248-019-0389-8.
5
A time scaling approach to develop an in vitro-in vivo correlation (IVIVC) model using a convolution-based technique.采用基于卷积的技术开发体外-体内相关性(IVIVC)模型的时间标度方法。
J Pharmacokinet Pharmacodyn. 2011 Oct;38(5):519-39. doi: 10.1007/s10928-011-9206-4. Epub 2011 Jul 7.
6
In vitro-in vivo correlation (IVIVC) models for metformin after administration of modified-release (MR) oral dosage forms to healthy human volunteers.在健康人类志愿者中给予缓释口服剂型后二甲双胍的体外-体内相关性(IVIVC)模型。
J Pharm Sci. 2001 Aug;90(8):1176-85. doi: 10.1002/jps.1071.
7
Convolution- and Deconvolution-Based Approaches for Prediction of Pharmacokinetic Parameters of Diltiazem Extended-Release Products in Flow-Through Cell Dissolution Tester.基于卷积和去卷积的方法预测在流通池溶出仪中测定的地尔硫䓬缓控释制剂的药代动力学参数。
AAPS PharmSciTech. 2022 Jul 26;23(6):202. doi: 10.1208/s12249-022-02361-2.
8
Application of an NLME-Stochastic Deconvolution Approach to Level A IVIVC Modeling.NLME随机去卷积方法在A水平体内-体外相关性(IVIVC)建模中的应用。
J Pharm Sci. 2017 Jul;106(7):1905-1916. doi: 10.1016/j.xphs.2017.03.015. Epub 2017 Mar 22.
9
Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.开发一种用于设计缓释口服剂型的具有生理相关性的群体药代动力学体外-体内相关性方法。
Mol Pharm. 2017 Jan 3;14(1):53-65. doi: 10.1021/acs.molpharmaceut.6b00677. Epub 2016 Dec 12.
10
Time Scaling for In Vitro-In Vivo Correlation: the Inverse Release Function (IRF) Approach.体外-体内相关性的时间标度:反向释放函数(IRF)方法。
AAPS J. 2018 Aug 29;20(6):95. doi: 10.1208/s12248-018-0250-5.

引用本文的文献

1
The Finite Absorption Time Concept Guiding Model Informed Drug & Generics Development in Clinical Pharmacology.有限吸收时间概念指导模型助力临床药理学中药物及仿制药的研发。
Pharm Res. 2025 Jun 5. doi: 10.1007/s11095-025-03878-4.
2
Physiologically Based Biopharmaceutics Modeling Coupled with Biopredictive Dissolution in Development of Bioequivalent Formulation for Mesalamine Enteric Coated Tablet: A Tough Nut to Crack.基于生理的生物药剂学建模结合生物预测溶出度在美沙拉嗪肠溶片生物等效制剂开发中的应用:一项棘手的任务。
AAPS PharmSciTech. 2024 Dec 2;26(1):1. doi: 10.1208/s12249-024-02990-9.
3
A convolution-based in vitro-in vivo correlation model for methylphenidate hydrochloride delayed-release and extended-release capsule.

本文引用的文献

1
Development of R packages: '' and '' for noncompartmental analysis (NCA).R包的开发:用于非房室分析(NCA)的“”和“” 。 (注:原文中两个引号处内容缺失)
Transl Clin Pharmacol. 2018 Mar;26(1):10-15. doi: 10.12793/tcp.2018.26.1.10. Epub 2018 Mar 16.
2
Deconvolution Analysis by Non-linear Regression Using a Convolution-Based Model: Comparison of Nonparametric and Parametric Approaches.基于卷积模型的非线性回归解卷积分析:非参数和参数方法的比较。
AAPS J. 2019 Dec 9;22(1):9. doi: 10.1208/s12248-019-0389-8.
3
A General Framework for Assessing In vitro/In vivo Correlation as a Tool for Maximizing the Benefit-Risk Ratio of a Treatment Using a Convolution-Based Modeling Approach.
基于卷积的盐酸哌甲酯延迟释放和延长释放胶囊的体外-体内相关性模型。
CPT Pharmacometrics Syst Pharmacol. 2024 Jan;13(1):132-142. doi: 10.1002/psp4.13067. Epub 2023 Oct 31.
4
Convolution-based approach for modeling the paliperidone extended release and Long-Acting Injectable (LAI) PK of once-, and three-monthly products administration and for optimizing the development of new LAI products.基于卷积的方法用于建模帕利哌酮延长释放和长效注射(LAI)制剂的单次和每三个月给药的 PK 特征,并用于优化新 LAI 产品的开发。
J Pharmacokinet Pharmacodyn. 2023 Apr;50(2):89-96. doi: 10.1007/s10928-022-09835-7. Epub 2022 Dec 9.
5
Population Pharmacokinetic Modelling and Simulation to Determine the Optimal Dose of Nanoparticulated Sorafenib to the Reference Sorafenib.群体药代动力学建模与模拟以确定纳米粒索拉非尼相对于参比索拉非尼的最佳剂量。
Pharmaceutics. 2021 Apr 28;13(5):629. doi: 10.3390/pharmaceutics13050629.
6
Screening of Bioequivalent Extended-Release Formulations for Metformin by Principal Component Analysis and Convolution-Based IVIVC Approach.基于主成分分析和卷积的 IVIVC 方法筛选二甲双胍生物等效缓释制剂。
AAPS J. 2021 Mar 4;23(2):38. doi: 10.1208/s12248-021-00559-z.
基于卷积建模方法评估体外/体内相关性作为最大化治疗获益-风险比的工具的一般框架。
CPT Pharmacometrics Syst Pharmacol. 2019 Feb;8(2):97-106. doi: 10.1002/psp4.12378. Epub 2019 Feb 5.
4
Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods.群体建模、模拟及基于模型的药物研发基础概念——第2部分:药代动力学建模方法介绍
CPT Pharmacometrics Syst Pharmacol. 2013 Apr 17;2(4):e38. doi: 10.1038/psp.2013.14.
5
A population approach to in vitro-in vivo correlation modelling for compounds with nonlinear kinetics.采用群体方法进行非线性动力学化合物的体外-体内相关模型研究。
J Pharmacokinet Pharmacodyn. 2011 Jun;38(3):317-32. doi: 10.1007/s10928-011-9195-3. Epub 2011 Mar 16.
6
The influence of averaging procedure on the accuracy of IVIVC predictions: immediate release dosage form case study.平均处理程序对 IVIVC 预测准确性的影响:即释剂型案例研究。
J Pharm Sci. 2010 Dec;99(12):5040-5. doi: 10.1002/jps.22209.
7
Compartmental analysis and its manifold applications to pharmacokinetics.房室分析及其在药代动力学中的多种应用。
AAPS J. 2010 Mar;12(1):61-72. doi: 10.1208/s12248-009-9160-x. Epub 2009 Nov 25.
8
The effects of averaging on accuracy of IVIVC model predictions.平均处理对 IVIVC 模型预测准确性的影响。
J Pharm Sci. 2009 Oct;98(10):3829-38. doi: 10.1002/jps.21662.
9
A comparison of the prediction accuracy of two IVIVC modelling techniques.两种体内-体外相关性(IVIVC)建模技术预测准确性的比较。
J Pharm Sci. 2008 Aug;97(8):3422-32. doi: 10.1002/jps.21220.
10
KINETIC ANALYSIS OF BLOOD LEVELS AND URINARY EXCRETION IN THE ABSORPTIVE PHASE AFTER SINGLE DOSES OF DRUG.单次给药后吸收期血药浓度及尿排泄的动力学分析
J Pharm Sci. 1964 Nov;53:1392-403. doi: 10.1002/jps.2600531126.